Galmed Pharmaceuticals Ltd.
GLMD
Price:
$3.46
Market Cap:
$5.21M
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a research a...[Read more]
Industry
Biotechnology
IPO Date
2014-03-13
Stock Exchange
NASDAQ
Ticker
GLMD
PE Ratio
[-0.36]
ROE
[-43.60%]
Current Ratio
[6.48]
Dividend Yield
[0%]
Enterprise Value
[3.26M]
Dividend History
The PE Ratio as of October 2024 (TTM) for Galmed Pharmaceuticals Ltd. (GLMD) is -0.36
According to Galmed Pharmaceuticals Ltd.’s latest financial reports and current stock price. The company's current PE Ratio is -0.36. This represents a change of -90.80% compared to the average of -3.91 of the last 4 quarters.
Galmed Pharmaceuticals Ltd. (GLMD) Historical PE Ratio (quarterly & annually)
How has GLMD PE Ratio performed in the past?
The mean historical PE Ratio of Galmed Pharmaceuticals Ltd. over the last ten years is -60.04. The current -0.36 PE Ratio has changed -40.04% with respect to the historical average. Over the past ten years (40 quarters), GLMD's PE Ratio was at its highest in in the June 2024 quarter at -0.40. The PE Ratio was at its lowest in in the September 2018 quarter at -898.87.
Average
-60.04
Median
-53.82
Minimum
-150.75
Maximum
-0.18
Galmed Pharmaceuticals Ltd. (GLMD) PE Ratio by Quarter and Year
Discovering the peaks and valleys of Galmed Pharmaceuticals Ltd. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 304.83%
Maximum Annual PE Ratio = -0.18
Minimum Annual Increase = -97.84%
Minimum Annual PE Ratio = -150.75
| Year | PE Ratio | Change |
|---|---|---|
| 2023 | -0.18 | -97.84% |
| 2022 | -8.12 | -51.69% |
| 2021 | -16.81 | -41.54% |
| 2020 | -28.75 | -63.58% |
| 2019 | -78.95 | -47.63% |
| 2018 | -150.75 | 31.84% |
| 2017 | -114.35 | 304.83% |
| 2016 | -28.25 | -70.39% |
| 2015 | -95.39 | 20.90% |
| 2014 | -78.89 | -24.71% |
Galmed Pharmaceuticals Ltd. (GLMD) Average PE Ratio
How has GLMD PE Ratio performed in the past?
The current PE Ratio of Galmed Pharmaceuticals Ltd. (GLMD) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-8.37
5-year avg
-26.56
10-year avg
-60.04
Galmed Pharmaceuticals Ltd. (GLMD) PE Ratio vs. Peers
How is GLMD’s PE Ratio compared to its peers?
Galmed Pharmaceuticals Ltd.’s PE Ratio is less than Affimed N.V. (0), greater than Abeona Therapeutics Inc. (-0.59), greater than Akebia Therapeutics, Inc. (-5.13), greater than Kodiak Sciences Inc. (-6.90), greater than Mereo BioPharma Group plc (-0.88), greater than Adverum Biotechnologies, Inc. (-19.19), greater than Adaptimmune Therapeutics plc (-1.69), greater than Pieris Pharmaceuticals, Inc. (-2.95), greater than PDS Biotechnology Corporation (-0.92), greater than Leap Therapeutics, Inc. (-2.80), greater than Fortress Biotech, Inc. (-1.52), greater than Mustang Bio, Inc. (-0.73), less than Achilles Therapeutics plc (-0.16), greater than Aptose Biosciences Inc. (-0.62), less than Fortress Biotech, Inc. (-0.15), greater than null (-0.73),
| Company | PE Ratio | Market cap |
|---|---|---|
| 0 | $50.40M | |
| -0.59 | $291.94M | |
| -5.13 | $279.68M | |
| -6.90 | $173.63M | |
| -0.88 | $701.16M | |
| -19.19 | $168.07M | |
| -1.69 | $215.17M | |
| -2.95 | $22.35M | |
| -0.92 | $114.14M | |
| -2.80 | $89.16M | |
| -1.52 | $49.89M | |
| -0.73 | $7.90M | |
| -0.16 | $40.68M | |
| -0.62 | $6.52M | |
| -0.15 | $52.15M | |
| -0.73 | $0 |
Build a custom stock screener for Galmed Pharmaceuticals Ltd. (GLMD) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Galmed Pharmaceuticals Ltd. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Galmed Pharmaceuticals Ltd. (GLMD) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Galmed Pharmaceuticals Ltd. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the PE Ratio?
How can you use the PE Ratio?
What is Galmed Pharmaceuticals Ltd.'s PE Ratio?
How is the PE Ratio calculated for Galmed Pharmaceuticals Ltd. (GLMD)?
What is the highest PE Ratio for Galmed Pharmaceuticals Ltd. (GLMD)?
What is the 3-year average PE Ratio for Galmed Pharmaceuticals Ltd. (GLMD)?
What is the 5-year average PE Ratio for Galmed Pharmaceuticals Ltd. (GLMD)?
How does the current PE Ratio for Galmed Pharmaceuticals Ltd. (GLMD) compare to its historical average?